---
title: Novo Nordisk (NVO)
layout: default
nav_order: 16
---

# Novo Nordisk
{: .fs-9 }

{: .label .label-purple }

Moat: 4/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $370 B

Novo Nordisk, a global healthcare company specializing in diabetes care, possesses a **wide moat**, primarily stemming from its **intangible assets**â€”specifically, its brand name, patents, and regulatory approvals.  These create a mini-monopoly in its market niches, allowing it to charge premium prices. This moat assessment is based on the framework described in Pat Dorsey's *The Little Book That Builds Wealth* and the Morgan Stanley report *Measuring the Moat*.  While Novo Nordisk's dominance in diabetes care is substantial, a rating of 4/5 reflects a degree of pessimism regarding the long-term durability of its moat due to increasing competition and biosimilar drugs, as echoed in *Eroding Moats* from Dorsey's book.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=NVO+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/NVO/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


Management receives a more guarded rating of **3/5**. While the company has historically been well-managed and has delivered strong returns on capital, several factors lead to this more cautious assessment:

* **Capital Allocation Decisions:**  While Novo Nordisk has generally been disciplined in its capital allocation, its forays outside of its core competency have been less successful.  The company has struggled to replicate its success in obesity care.  Furthermore, its R&D spending, while substantial, has not always translated into blockbuster drugs at the same pace as in the past. These less effective capital allocation moves contribute to a somewhat pessimistic rating for management, as warned against in Dorsey's *What's a Moat Worth*.
* **Communication:** While recent management has improved investor communication by providing clearer guidance and discussing strategic priorities, a history of opaque communication and a tendency to downplay risks (especially regarding competition from biosimilars) warrant a less optimistic view, as stressed in Damodaran's *The Dark Side of Valuation: A Jedi Guide to Valuing Difficult-to-value Companies*.
* **Compensation:** Executive compensation, especially for top management, is significant. While some compensation is tied to performance metrics like EPS growth, other packages include grants of stock options, a practice criticized by Graham and Buffett for potentially creating misaligned incentives, as discussed in *The Essays of Warren Buffett*.
* **Insider Ownership:** Insider ownership appears low, potentially reducing the alignment of management's interests with those of outside shareholders. This aligns with the skeptical perspective advocated in *Corporate Governance* within Buffett's essays.
* **History and Experience:** While current leadership has a relatively short track record, the company's long history and deep expertise in diabetes care provide some support for a stable and knowledgeable management team. However, their ability to adapt to the changing competitive landscape remains a concern, justifying a less enthusiastic outlook, as explored in Fisher's *Common Stocks and Uncommon Profits*.

{: .warning }

**Recent Concerns:**  Novo Nordisk faces increasing competition from biosimilar and generic versions of its key drugs, a significant threat to its long-term pricing power.  There are also concerns about the sustainability of the explosive growth in the GLP-1 market, especially in obesity care.  The management's comments in recent earnings calls (e.g., Q1 2023) acknowledge this increased competition, but their confidence in their ability to maintain market share and launch new products warrants a cautious perspective.

{: .new }

**Potential Catalysts:**  Novo Nordisk's pipeline of new drugs and drug delivery systems, especially in areas beyond diabetes, could drive future growth.  The expansion of GLP-1 drugs into new therapeutic areas, such as Alzheimer's disease, is a potential catalyst, but its success remains uncertain.  The launch of new oral formulations of its existing drugs could also boost sales. Given the uncertainty surrounding these catalysts, a moderate rating of 2/5 is assigned.


### Business Overview

* **Revenues Distribution:** Novo Nordisk's revenue is primarily derived from diabetes and obesity care products, with GLP-1 drugs like Ozempic and Wegovy driving significant growth. Sales are distributed globally, with a strong presence in North America, Europe, and increasingly in emerging markets. The geographical distribution of revenues makes it exposed to country risks, though it has historically been a strength as discussed in *Valuation in Emerging Markets* by Damodaran.
* **Industry Trends:** The diabetes and obesity care markets are growing rapidly, driven by aging populations and lifestyle changes. However, increasing competition from biosimilars and new entrants poses a challenge. The GLP-1 segment is currently experiencing hyper-growth, but as discussed in Michael Mauboussin's report on *Moats*, the longer and stronger growth, the more likely it is to attract new competition.
* **Margins:** Novo Nordisk historically enjoys high operating margins thanks to its patented products and dominant market share. However, margins are facing downward pressure due to pricing competition and increased R&D spending, a dynamic explored in Dorsey's *Eroding Moats*.
* **Competitive Landscape:**  Novo Nordisk faces competition from established pharmaceutical giants like Eli Lilly and Sanofi, as well as from smaller biotech firms. Competition is particularly fierce in the GLP-1 market.  As pointed out in Dorsey's *Mistaken Moats*, simply having high market share is not enough of a moat if competitors can quickly catch up.  The company needs to demonstrate through innovation and pricing power that it can maintain its leadership position.
* **Differentiation:** Novo Nordisk differentiates itself through its focus on diabetes and obesity care, its deep expertise in these therapeutic areas, and its strong relationships with doctors and patients. However, as discussed in Fisher's work, simply being better is not sufficient unless it is translated into sustainable competitive advantage. The long term success lies in translating these advantages into superior returns on invested capital, which in the case of Novo Nordisk, are starting to decrease.


### Financial Analysis

Novo Nordisk's financials have historically been very strong, with high returns on equity and robust cash flows. However, recent trends show some potential areas of concern:

* **Revenue Growth:** Revenue growth has been impressive, driven primarily by GLP-1 drugs.  However, the sustainability of this growth in the face of increasing competition is uncertain.  In Q2 2022 call, management expects sales to increase by more than 15% for the rest of the fiscal year, and they expect sales of obesity care segment to increase by almost 40%.
* **Margins:** Operating margins have been declining slightly in recent years, primarily due to increased competition and R&D spending. In their Q2 2022 earnings call, the company noted that the operating margin had reduced because of higher sales and distribution costs, along with higher R&D investments. In their Q3 2022 call they noted that the operating margin was lower, primarily due to higher R&D expenses to support further portfolio progression and launch activities and due to currency effects.
* **Return on Invested Capital (ROIC):**  Novo Nordisk's ROIC has historically been very high, a key indicator of its competitive advantage. However, ROIC is now starting to decline, albeit slowly.  This trend needs to be closely monitored.  This is calculated using information from recent earnings calls, including reinvestment rates and taxes, with data from 2019 to 2022. The declining ROIC trend is a concerning sign as explained in Dorsey's *Finding Moats*.

### Valuation

Using a discounted cash flow (DCF) model, with a pessimistic outlook on future growth and margins, I arrive at an estimated value of **$370 billion**. 

{: .important }

**Valuation Assumptions and Calculations:**

1. **Revenue Growth:** Assuming revenue growth will gradually decrease over the next 10 years, from 10% to 3%, reflecting increased competition and pricing pressure.
2. **Operating Margin:**  Assuming the operating margin will stabilize at 35%, lower than its historical peak, due to pricing pressure and increasing R&D expenses.
3. **Reinvestment Rate:** Estimated at 10% in the stable growth period, reflecting the company's need to invest to maintain its competitive position.
4. **Cost of Capital:**  Estimated at 7%, based on a risk-free rate of 3.8%, a beta of 0.92, a risk premium of 4%, and a debt ratio of 15%.
5. **Terminal Value:** Calculated using a perpetuity growth model, with a 3% growth rate and a return on capital of 10%. 

Using these inputs in a DCF model, and discounting the resulting cash flows, yields a present value of $370 billion.  This valuation is clearly lower than the company's current market capitalization.  However, as emphasized in Graham's *The Intelligent Investor*, a margin of safety is essential, and even great companies can be poor investments if purchased at excessive prices. This is further emphasized in *What's a Moat Worth* by Dorsey, where he says that you're unlikely to ever buy at the "best" price and "You can be certain that you're making a mistake...if you refuse to sell the shares of that marvelous company unless they're trading higher".  A pessimistic outlook on competition and growth are also key to making sound investment decisions as discussed in *Valuation Viagra* within *The Essays of Warren Buffet*.

This valuation approach is inspired by Michael Burry's detailed and granular focus on financial statements and his willingness to take a contrarian view, as exemplified in the provided MSN Money articles.  Like Burry, this analysis incorporates a pessimistic outlook and utilizes multiple sources of information, including SEC filings, earnings calls, and industry reports, to make informed judgments about the business and its valuation.  This aligns with Dorsey's guidance in *Finding Moats* and Graham's philosophy in *Security Analysis* and *The Intelligent Investor*.
